Cryosite Limited (CTE) Fair Value & Analysis
Healthcare · AU · Market cap A$61.0M
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price −4.0% over the past month.
A solid business, but screening 29% overvalued on our models.
What matters now
- A high-quality business (quality 73/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (A$0.6200 to A$2.12). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range A$0.2853 – A$1.30 · fair‑value band A$0.6200 – A$2.12 · the A$1.20 price screens above the A$0.8500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Cryosite Limited (CTE) currently trades at A$1.20, while our model-based Fair Value estimate is A$0.8500, implying the stock looks roughly 29.2% overvalued today. The Quality Score stands at 73/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Cryosite Limited generated revenue of A$15.7M at a net margin of 13.9%. Revenue grew 24.6% year over year. It earns a return on equity of 88.8%. The balance sheet holds a net cash position of A$2.8M. Fundamentals as of Jul 12, 2026
Our scenario range runs from A$0.6200 (bear case) to A$2.12 (bull case); at A$1.20, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 82% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -29%, CTE screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (A$1.63) versus Asset-Based (A$0.0300). Highest evidence: Growth DCF (80).
Notify me when CTE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 75
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments.
Full company description
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cryosite Limited reported revenue of A$14.1M in FY2025 versus A$10.0M in FY2021, a compound +8.9%/yr. Reported net income was A$1.9M in FY2025, compounding +30.4%/yr from FY2021.
of which total revenue +3.3 pp · buybacks/dilution −0.4 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
CTE screens 29% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Cryosite Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cryosite Limited (CTE) overvalued or undervalued?
What is the fair value of CTE?
What is the quality score of CTE?
What is the revenue of Cryosite Limited (CTE)?
What is the net profit margin of CTE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cryosite Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.